

CHINA NEW ENERGY GROUP COMPANY

8514 South Sagewood Road
Spokane, WA, 99223

1.509.230.1177
www.thriveprecision.health
guy@thrivebiosafety.com

Quarterly Report – Q3 2024

For the period ending September 30, 2024 (unaudited) (the “Reporting Period”)

Outstanding Shares

The number of shares outstanding of our Common Stock was:

7,342,532,492 as of September 30, 2024 (*Current Reporting Period Date or More Recent Date*)

7,342,532,492 as of December 31, 2023

Shell Status

Indicate by check mark whether the company is a shell company (as defined in Rule 405 of the Securities Act of 1933, Rule 12b-2 of the Exchange Act of 1934 and Rule 15c2-11 of the Exchange Act of 1934):

Yes: No:

Indicate by check mark whether the company’s shell status has changed since the previous reporting period:

Yes: No:

Change in Control

Indicate by check mark whether a Change in Control⁴ of the company has occurred during this reporting period:

Yes: No:

⁴ “Change in Control” shall mean any events resulting in:

- (i) Any “person” (as such term is used in Sections 13(d) and 14(d) of the Exchange Act) becoming the “beneficial owner” (as defined in Rule 13d-3 of the Exchange Act), directly or indirectly, of securities of the Company representing fifty percent (50%) or more of the total voting power represented by the Company’s then outstanding voting securities;
- (ii) The consummation of the sale or disposition by the Company of all or substantially all of the Company’s assets;
- (iii) A change in the composition of the Board occurring within a two (2)-year period, as a result of which fewer than a majority of the directors are directors immediately prior to such change; or
- (iv) The consummation of a merger or consolidation of the Company with any other corporation, other than a merger or consolidation which would result in the voting securities of the Company outstanding immediately prior thereto continuing to represent (either by remaining outstanding or by being converted into voting securities of the surviving entity or its parent) at least fifty percent (50%) of the total voting power represented by the voting securities of the Company or such surviving entity or its parent outstanding immediately after such merger or consolidation.

1) Name and address(es) of the issuer and its predecessors (if any)

In answering this item, provide the current name of the issuer and names used by predecessor entities, along with the dates of the name changes.

China New Energy Group, Company.

02/15/2024 China New Energy Group Company changed its name from Thrive Precision Health Inc.

10/04/2023 Thrive Precision Health Inc. changed its name from Thrive Global Biosafety Inc.

04/03/2023 Thrive Global Biosafety Inc. changed its name from China New Energy Group Company

05/29/2008 CNER Symbol change from TVHT to CNER

Travel Hunt Holdings, Inc. until 5-2008

Current State and Date of Incorporation or Registration: Wyoming, November 28, 2023

Standing in this jurisdiction: (e.g. active, default, inactive): Active

Prior Incorporation Information for the issuer and any predecessors during the past five years:

02/15/2024 Thrive Precision Health Inc. changed its name back to New China Energy Group Company in the State of Wyoming

10/28/2023 Thrive Precision Health Inc., redomiciled in the State of Wyoming

10/04/2023 Thrive Precision Health Inc. changed its name from Thrive Global Biosafety Inc. in the State of Delaware

04/03/2023 Thrive Global Biosafety Inc. changed its name from China New Energy Group Company in the State of Delaware

Describe any trading suspension or halt orders issued by the SEC or FINRA concerning the issuer or its predecessors since inception:

None

List any stock split, dividend, recapitalization, merger, acquisition, spin-off, or reorganization either currently anticipated or that occurred within the past 12 months:

None

Address of the issuer's principal executive office:

8514 South Sagewood Road
Spokane, WA 99223

Address of the issuer's principal place of business:

Check if principal executive office and principal place of business are the same address:

Has the issuer or any of its predecessors been in bankruptcy, receivership, or any similar proceeding in the past five years?

No: Yes: If Yes, provide additional details below:

2) Security Information

Transfer Agent

Name: Equiniti Trust Company
Phone: 651-306-4341
Email: Valeen.Nowicki@equiniti.com
Address: 1110 Centre Pointe Curve Suit 101, Mendota Heights, MN 55120

Publicly Quoted or Traded Securities:

The goal of this section is to provide a clear understanding of the share information for its publicly quoted or traded equity securities. Use the fields below to provide the information, as applicable, for all outstanding classes of securities that are publicly traded/quoted.

Trading symbol: CNER
Exact title and class of securities outstanding: Common
CUSIP: 16944P109
Par or stated value: .001
Total shares authorized: 10,000,000,000 as of date: September 30, 2024
Total shares outstanding: 7,342,532,492 as of date: September 30, 2024
Total number of shareholders of record: 195 as of date: September 30, 2024

Please provide the above-referenced information for all other publicly quoted or traded securities of the issuer.

Other classes of authorized or outstanding equity securities that do not have a trading symbol:

The goal of this section is to provide a clear understanding of the share information for its other classes of authorized or outstanding equity securities (e.g., preferred shares that do not have a trading symbol). Use the fields below to provide the information, as applicable, for all other authorized or outstanding equity securities.

Exact title and class of the security: Preferred
Par or stated value: 0.001
Total shares authorized: 10,000,000 as of date: September 30, 2024
Total shares outstanding: 0 as of date: September 30, 2024
Total number of shareholders of record: 0 as of date: September 30, 2024

Please provide the above-referenced information for all other classes of authorized or outstanding equity securities.

Security Description:

The goal of this section is to provide a clear understanding of the material rights and privileges of the securities issued by the company. Please provide the below information for each class of the company's equity securities, as applicable:

1. For common equity, describe any dividend, voting and preemption rights.

Par value of \$.001 with a 1:1 voting right

2. For preferred stock, describe the dividend, voting, conversion, and liquidation rights as well as redemption or sinking fund provisions.

Conversion 200:1

3. Describe any other material rights of common or preferred stockholders.

None

4. Describe any material modifications to rights of holders of the company's securities that have occurred over the reporting period covered by this report.

None

3) Issuance History

The goal of this section is to provide disclosure with respect to each event that resulted in any changes to the total shares outstanding of any class of the issuer's securities in the past two completed fiscal years and any subsequent interim period.

Disclosure under this item shall include, in chronological order, all offerings and issuances of securities, including debt convertible into equity securities, whether private or public, and all shares, or any other securities or options to acquire such securities, issued for services. Using the tabular format below, please describe these events.

A. Changes to the Number of Outstanding Shares for the two most recently completed fiscal years and any subsequent period.

Indicate by check mark whether there were any changes to the number of outstanding shares within the past two completed fiscal years:

No: Yes: (If yes, you must complete the table below)

Shares Outstanding <u>Opening Balance</u> : Date <u>12.31.22</u> Common: <u>107,070,281</u> Preferred: <u>10,000,000</u>			*Right-click the rows below and select "Insert" to add rows as needed.						
Date of Transaction	Transaction type (e.g., new issuance, cancellation, shares returned to treasury)	Number of Shares Issued (or cancelled)	Class of Securities	Value of shares issued (\$/per share) at Issuance	Were the shares issued at a discount to market price at the time of	Individual/ Entity Shares were issued to. ***You must disclose the control person(s) for any entities listed.	Reason for share issuance (e.g. for cash or debt conversion) - OR- Nature of Services Provided	Restricted or Unrestricted as of this filing.	Exemption or Registration Type.

					issuance? (Yes/No)				
<u>3.13.23</u>	<u>New</u>	430,595,270	<u>Common</u>	<u>.01</u>	<u>No</u>	Hackett, CP As Trustee For Hackett Family Trust, Simon Hackett	<u>Conversion</u>	<u>Restricted</u>	<u>144</u>
<u>3.13.23</u>	<u>New</u>	319,325,355	<u>Common</u>	<u>.01</u>	<u>No</u>	Todd Leong	<u>Conversion</u>	<u>Restricted</u>	<u>144</u>
<u>3.13.23</u>	<u>New</u>	15,964,205	<u>Common</u>	<u>.01</u>	<u>No</u>	Anne M. Vertovec	<u>Conversion</u>	<u>Restricted</u>	<u>144</u>
<u>3.13.23</u>	<u>New</u>	53,183,615	<u>Common</u>	<u>.01</u>	<u>No</u>	Cynthia R. Klein	<u>Conversion</u>	<u>Restricted</u>	<u>144</u>
<u>3.13.23</u>	<u>New</u>	10,626,585	<u>Common</u>	<u>.01</u>	<u>No</u>	Sharon Anderson Morris	<u>Conversion</u>	<u>Restricted</u>	<u>144</u>
<u>3.13.23</u>	<u>New</u>	26,520,860	<u>Common</u>	<u>.01</u>	<u>No</u>	Robert F. Anderson Revocable Trust, Robert Anderson	<u>Conversion</u>	<u>Restricted</u>	<u>144</u>
<u>3.13.23</u>	<u>New</u>	53,031,730	<u>Common</u>	<u>.01</u>	<u>No</u>	Albert O. Braun Trust UAD 4/26/2017, Albert Bruan	<u>Conversion</u>	<u>Restricted</u>	<u>144</u>
<u>3.13.23</u>	<u>New</u>	1,046,915	<u>Common</u>	<u>.01</u>	<u>No</u>	Witold Ostrenko	<u>Conversion</u>	<u>Restricted</u>	<u>144</u>
<u>3.13.23</u>	<u>New</u>	104,664,305	<u>Common</u>	<u>.01</u>	<u>No</u>	Paul Alston	<u>Conversion</u>	<u>Restricted</u>	<u>144</u>
<u>3.13.23</u>	<u>New</u>	52,332,245	<u>Common</u>	<u>.01</u>	<u>No</u>	Henry Morgan Hilliard & Tana Felts Hilliard, JTROS	<u>Conversion</u>	<u>Restricted</u>	<u>144</u>
<u>3.13.23</u>	<u>New</u>	10,436,035	<u>Common</u>	<u>.01</u>	<u>No</u>	Kaulu Holdings, LLC Peter Ciaccia	<u>Conversion</u>	<u>Restricted</u>	<u>144</u>
<u>3.13.23</u>	<u>New</u>	10,409,580	<u>Common</u>	<u>.01</u>	<u>No</u>	Yashna Shetty	<u>Conversion</u>	<u>Restricted</u>	<u>144</u>
<u>3.13.23</u>	<u>New</u>	20,701,685	<u>Common</u>	<u>.01</u>	<u>No</u>	Theresa L. Newsome with Karalyn I. Windebank and John Kyle Newsome, JTROS	<u>Conversion</u>	<u>Restricted</u>	<u>144</u>
<u>3.13.23</u>	<u>New</u>	17,038,500	<u>Common</u>	<u>.01</u>	<u>No</u>	Ann Vertovec	<u>Conversion</u>	<u>Restricted</u>	<u>144</u>
<u>3.13.23</u>	<u>New</u>	1,020,275	<u>Common</u>	<u>.01</u>	<u>No</u>	Arthur St. C. Wright	<u>Conversion</u>	<u>Restricted</u>	<u>144</u>

<u>3.13.23</u>	<u>New</u>	101,278,620	<u>Common</u>	<u>.01</u>	<u>No</u>	Nicole MaClaren	<u>Conversion</u>	<u>Restricted</u>	<u>144</u>
<u>3.13.23</u>	<u>New</u>	50,517,580	<u>Common</u>	<u>.01</u>	<u>No</u>	Joseph C. Roche and Karen C. Roche, JTROS	<u>Conversion</u>	<u>Restricted</u>	<u>144</u>
<u>3.13.23</u>	<u>New</u>	1,961,000,000	<u>Common</u>	<u>.01</u>	<u>No</u>	Guy M. Zajonc	<u>Conversion</u>	<u>Restricted</u>	<u>144</u>
<u>3.13.23</u>	<u>New</u>	1,147,000,000	<u>Common</u>	<u>.01</u>	<u>No</u>	Michael T. Pfeffer	<u>Conversion</u>	<u>Restricted</u>	<u>144</u>
<u>3.13.23</u>	<u>New</u>	388,500,000	<u>Common</u>	<u>.01</u>	<u>No</u>	Sharon Anderson Morris	<u>Conversion</u>	<u>Restricted</u>	<u>144</u>
<u>3.13.23</u>	<u>New</u>	296,000,000	<u>Common</u>	<u>.01</u>	<u>No</u>	Lisa Bradley	<u>Conversion</u>	<u>Restricted</u>	<u>144</u>
<u>3.13.23</u>	<u>New</u>	150,000,000	<u>Common</u>	<u>.01</u>	<u>No</u>	Felix Inc. <u>Lawrence McGean</u>	<u>Conversion</u>	<u>Restricted</u>	<u>144</u>
<u>3.13.23</u>	<u>New</u>	150,000,000	<u>Common</u>	<u>.01</u>	<u>No</u>	Comfort Inc. <u>Lawrence McGean</u>	<u>Conversion</u>	<u>Restricted</u>	<u>144</u>
<u>3.13.23</u>	<u>New</u>	150,000,000	<u>Common</u>	<u>.01</u>	<u>No</u>	Lago Inc. Colin Thompson	<u>Conversion</u>	<u>Restricted</u>	<u>144</u>
<u>3.13.23</u>	<u>New</u>	129,166,600	<u>Common</u>	<u>.01</u>	<u>No</u>	Ishlex Investment Corp Ltd Gordon Sklenka	<u>Conversion</u>	<u>Restricted</u>	<u>144</u>
<u>3.13.23</u>	<u>New</u>	129,166,600	<u>Common</u>	<u>.01</u>	<u>No</u>	Warmstream Investments Ltd Gary Handley	<u>Conversion</u>	<u>Restricted</u>	<u>144</u>
<u>3.13.23</u>	<u>New</u>	129,166,600	<u>Common</u>	<u>.01</u>	<u>No</u>	Wilura Capital Corp. Charles Ryan	<u>Conversion</u>	<u>Restricted</u>	<u>144</u>
<u>3.13.23</u>	<u>New</u>	150,000,000	<u>Common</u>	<u>.01</u>	<u>No</u>	BT Global Holdings Pty Guy Le Page	<u>Conversion</u>	<u>Restricted</u>	<u>144</u>
<u>3.13.23</u>	<u>New</u>	118,750,000	<u>Common</u>	<u>.01</u>	<u>No</u>	BG Development Fund Pty Ltd Bryce Gould	<u>Conversion</u>	<u>Restricted</u>	<u>144</u>
<u>3.13.23</u>	<u>New</u>	118,750,200	<u>Common</u>	<u>.01</u>	<u>No</u>	Joarch Jagia Investments Pty Ltd Mark Skiffington	<u>Conversion</u>	<u>Restricted</u>	<u>144</u>
<u>3.13.23</u>	<u>New</u>	215,000,000	<u>Common</u>	<u>.01</u>	<u>No</u>	Graycliff Consulting GmbH Susann Prochnow	<u>Conversion</u>	<u>Restricted</u>	<u>144</u>

<u>3.13.23</u>	<u>New</u>	350,000,000	<u>Common</u>	<u>.01</u>	<u>No</u>	Onyx Capital GmbH Torston Prochnow	<u>Conversion</u>	<u>Restricted</u>	<u>144</u>
<u>3.13.23</u>	<u>New</u>	210,000,000	<u>Common</u>	<u>.01</u>	<u>No</u>	Lilly Rose Prochnow	<u>Conversion</u>	<u>Restricted</u>	<u>144</u>
<u>3.24.23</u>	<u>New</u>	12,333,395	<u>Common</u>	<u>.01</u>	<u>No</u>	Anne M. Vertovec	<u>Conversion</u>	<u>Restricted</u>	<u>144</u>
<u>3.24.23</u>	<u>New</u>	6,166,605	<u>Common</u>	<u>.01</u>	<u>No</u>	Robert F. Anderson Revocable Trust, Robert Anderson	<u>Conversion</u>	<u>Restricted</u>	<u>144</u>
<u>3.24.23</u>	<u>New</u>	24,666,605	<u>Common</u>	<u>.01</u>	<u>No</u>	Albert O. Braun Trust UAD 4/26/2017, Albert Braun	<u>Conversion</u>	<u>Restricted</u>	<u>144</u>
<u>3.24.23</u>	<u>New</u>	616,605	<u>Common</u>	<u>.01</u>	<u>No</u>	Arthur St. C. Wright	<u>Conversion</u>	<u>Restricted</u>	<u>144</u>
<u>3.24.23</u>	<u>New</u>	30,833,395	<u>Common</u>	<u>.01</u>	<u>No</u>	Joseph C. Roche and Karen C. Roche, JTROS	<u>Conversion</u>	<u>Restricted</u>	<u>144</u>
<u>3.24.23</u>	<u>New</u>	6,166,605	<u>Common</u>	<u>.01</u>	<u>No</u>	Ann M. Vertovec and Betty J. Vertovec, JTROS	<u>Conversion</u>	<u>Restricted</u>	<u>144</u>
<u>3.24.23</u>	<u>New</u>	7,893,395	<u>Common</u>	<u>.01</u>	<u>No</u>	Brian Hargreaves	<u>Conversion</u>	<u>Restricted</u>	<u>144</u>
<u>10.05.23</u>	<u>New</u>	<u>3,000,000</u>	<u>Common</u>	<u>.01</u>	<u>No</u>	<u>Dominique Martinez</u>	<u>Cash</u>	<u>Restricted</u>	<u>144</u>
<u>10.05.23</u>	<u>New</u>	<u>2,500,000</u>	<u>Common</u>	<u>.01</u>	<u>No</u>	<u>Michael Beer</u>	<u>Cash</u>	<u>Restricted</u>	<u>144</u>
<u>10.05.23</u>	<u>New</u>	<u>2,500,000</u>	<u>Common</u>	<u>.01</u>	<u>No</u>	<u>Kaulu Holdings, LLC, Brett Seitman</u>	<u>Cash</u>	<u>Restricted</u>	<u>144</u>
<u>10.05.23</u>	<u>New</u>	<u>2,000,000</u>	<u>Common</u>	<u>.01</u>	<u>No</u>	<u>Comfort Inc., Larry McGean</u>	<u>Cash</u>	<u>Restricted</u>	<u>144</u>
<u>10.05.23</u>	<u>New</u>	<u>50,000,000</u>	<u>Common</u>	<u>.01</u>	<u>No</u>	<u>Knutz Holdings LLC, Jonathan Knutz</u>	<u>Cash</u>	<u>Restricted</u>	<u>144</u>
<u>10.05.23</u>	<u>New</u>	<u>4,371,233</u>	<u>Common</u>	<u>.01</u>	<u>No</u>	<u>BT Global Holdings Pty Ltf, Guy LePage</u>	<u>Conversion</u>	<u>Restricted</u>	<u>144</u>
<u>10.05.23</u>	<u>New</u>	<u>2,069,863</u>	<u>Common</u>	<u>.01</u>	<u>No</u>	<u>Ishlex Investment Corp Ltd, Gordon Sklenka</u>	<u>Conversion</u>	<u>Restricted</u>	<u>144</u>
<u>10.05.23</u>	<u>New</u>	<u>2,599,863</u>	<u>Common</u>	<u>.01</u>	<u>No</u>	<u>Brenda Chisholm</u>	<u>Conversion</u>	<u>Restricted</u>	<u>144</u>

<u>10.05.23</u>	<u>New</u>	<u>1,039,945</u>	<u>Common</u>	<u>.01</u>	<u>No</u>	<u>Michael Gardner</u>	<u>Conversion</u>	<u>Restricted</u>	<u>144</u>
<u>10.05.23</u>	<u>New</u>	<u>511,342</u>	<u>Common</u>	<u>.01</u>	<u>No</u>	<u>Bohdan Leshchyshen</u>	<u>Conversion</u>	<u>Restricted</u>	<u>144</u>
<u>10.05.23</u>	<u>New</u>	<u>5,000,000</u>	<u>Common</u>	<u>.01</u>	<u>No</u>	<u>Synergy Wound Solutions Asset Mgmt Trust, Kent Clark</u>	<u>Conversion</u>	<u>Restricted</u>	<u>144</u>
Shares Outstanding on Date of This Report: <u>Ending Balance:</u> <u>Date 09.30.2024</u> <u>Common: 7,342,532,492</u> <u>Preferred: 0</u>									

Example: A company with a fiscal year end of December 31st 2023, in addressing this item for its Annual Report, would include any events that resulted in changes to any class of its outstanding shares from the period beginning on January 1, 2022 through June 30, 2024 pursuant to the tabular format above.

*****Control persons for any entities in the table above must be disclosed in the table or in a footnote here.**

Use the space below to provide any additional details, including footnotes to the table above:

On March 7, 2023 the total authorized stock was increased to 10,000,000,000 with a par value of \$.001

B. Promissory and Convertible Notes

Indicate by check mark whether there are any outstanding promissory, convertible notes, convertible debentures, or any other debt instruments that may be converted into a class of the issuer's equity securities:

No: Yes: (If yes, you must complete the table below)

<u>Date of Note Issuance</u>	<u>Outstanding Balance (\$)</u>	<u>Principal Amount at Issuance (\$)</u>	<u>Interest Accrued (\$)</u>	<u>Maturity Date</u>	<u>Conversion Terms (e.g. pricing mechanism for determining conversion of instrument to shares)</u>	<u>Name of Noteholder.</u> <small>*** You must disclose the control person(s) for any entities listed.</small>	<u>Reason for Issuance (e.g. Loan, Services, etc.)</u>
<u>08/15/2023</u>	<u>105,632.27</u>	<u>98,932.00</u>	<u>6,700.27</u>	<u>08/15/2024</u>	<u>Converts upon a registered financing at the registered price</u>	<u>Lance Wallace</u>	<u>Loan</u>
<u>08/25/2023</u>	<u>52,716.70</u>	<u>49,449.00</u>	<u>3267.70</u>	<u>08/25/2024</u>	<u>Converts upon a registered financing at the registered price</u>	<u>Lance Wallace</u>	<u>Loan</u>
<u>11/24/2023</u>	<u>52,556.16</u>	<u>50,000.00</u>	<u>2,556.16</u>	<u>11/24/2024</u>	<u>Converts upon a registered financing at the registered price</u>	<u>Mark DeBell</u>	<u>Loan</u>
<u>12/08/2023</u>	<u>262,205.48</u>	<u>250,000.00</u>	<u>12,205.48</u>	<u>12/08/2024</u>	<u>Converts upon a registered financing</u>	<u>Lance Wallace</u>	<u>Loan</u>

					at the registered price		
01/30/2024	26,002.74	25,000.00	1,002.74	1/30/2025	Converts upon a registered financing at the registered price	Lance Wallace	Loan
05/24/2024	-5,106.03	-5,000.00	-106.53	Payment	Payment	Lance Wallace	Loan repayment
06/05/2024	774,142.28	759,534.25 ¹	14,608.03	2/22/2025	Converts upon a registered financing at the registered price	Knutz Holdings, LLC	Loan
07/10/2024	253,389.86	250,000.00	3,369.86	07/10/2025	Converts upon a registered financing at the registered price	Knutz Holdings LLC	Loan

***Control persons for any entities in the table above must be disclosed in the table or in a footnote here.

Use the space below to provide any additional details, including footnotes to the table above:

1. Promissory Convertible Note was transferred from Thrive Precision Health Inc., domiciled in Florida to Thrive Precision Health Inc., domiciled in Nevada on June 5, 2024. Thrive Precision Health Inc., Nevada is a wholly owned subsidiary of China New Energy Group Company.

4) Issuer's Business, Products and Services

The purpose of this section is to provide a clear description of the issuer's current operations. Ensure that these descriptions are updated on the Company's Profile on www.OTCMarkets.com.

A. Summarize the issuer's business operations (If the issuer does not have current operations, state "no operations")

As of March 15, 2023, CNER acquired Thrive Testing and Biosafety Inc., has assumed the business of biodefense with operations in Spokane WA and Hawaii. CNER is no longer a shell company as of March 15, 2023. On October 4, 2023, Thrive changed its name to Thrive Precision Health Inc., and announced it will focus on Precision Diabetes Care through the acquiring and opening of clinics across the USA and Internationally. On February 15, 2024 Thrive Precision Health Inc., changed its name back to China New Energy Group Company.

B. List any subsidiaries, parent company, or affiliated companies.

China New Energy Group Company is the parent company, formerly named Thrive Precision Health Inc. and is domiciled in the State of Wyoming

Thrive Precision Health Inc., is a wholly owned subsidiary of China New Energy Group Company and is now redomiciled in the State of Wyoming

Thrive Testing and Biosafety Inc. is a wholly owned subsidiary of China New Energy Group Company. was redomiciled in the State of Wyoming from the State of Delaware

Thrive Precision Health Hawaii, Inc., is a wholly owned subsidiary of China New Energy Group Company and is incorporated in the State of Hawaii

Thrive Precision Health USA Inc. is a wholly owned subsidiary of China New Energy Group Company and is incorporated in the state of Wyoming.

C. Describe the issuers' principal products or services.

Thrive Precision Health Inc ("TPH"), is focused on the institutionalization of diabetes care through establishing a digital platform that can scale to thousands of clinics across the USA and Internationally. We are working with established clinics that already specialize in diabetes care and bringing in three cutting-edge technologies to make them even better. Our goal is to provide top-notch care to patients worldwide, with a seamless digital experience. And we're aiming for a healthy profit margin through technology adoption and digital patient /clinician engagement which means a strong and sustainable business for everyone involved."

Thrive Precision Health Innovations, Inc. (formerly Thrive Testing and Biosafety Inc. ("Thrive")) will be the technology research and development arm, works with leading research and development companies around the world to license enabling technology and adapting it specially to better our clinical and patient operations. Thrive will also externally license to other providers especially in the area of Biosafety. Testing of Bacteria and Viruses on surfaces, in water, in air and in humans in a decentralized basis will speed up detection capabilities with the goal to create a real-time global early warning system and to secure our clinics and patients as well as other clinics. Thrive's goal is to use this system to identify disease breakouts before the next pandemic happens. Thrive's core strategy is to acquire enabling technology companies and integrate all the technology under one roof, one platform to provide seamless execution on a global scale.

5) Issuer's Facilities

The goal of this section is to provide investors with a clear understanding of all assets, properties or facilities owned, used or leased by the issuer and the extent in which the facilities are utilized.

In responding to this item, please clearly describe the assets, properties or facilities of the issuer. Describe the location of office space, data centers, principal plants, and other property of the issuer and describe the condition of the properties. Specify if the assets, properties, or facilities are owned or leased and the terms of their leases. If the issuer does not have complete ownership or control of the property, describe the limitations on the ownership.

TPH previously announced its intention to acquire the assets or shares two clinics currently operating in Arizona and has withdrawn its intention due to due diligence deficiencies in these operations. TPH has previously incorporated Thrive Precision Health (USA) Inc. (TPH US) to operate as a clinic (or network of clinics) in mainland USA and incorporated Thrive Precision Health Hawaii, Inc ("TPH HI") to operate as a clinic (or network of clinics) in Hawaii. Currently, TPH Hawaii has appointed a medical director and has contracted multiple providers to support a Direct to Consumer – Telehealth virtual clinic in Hawaii offering product to pre-diabetic and overweight patients. The Telehealth platform is intended to launch in Arizona in Q3-Q4 2024.

6) All Officers, Directors, and Control Persons of the Company

Using the table below, please provide information, as of the period end date of this report, regarding all officers and directors of the company, or any person that performs a similar function, regardless of the number of shares they own.

In addition, list all individuals or entities controlling 5% or more of any class of the issuer's securities.

If any insiders listed are corporate shareholders or entities, provide the name and address of the person(s) beneficially owning or controlling such corporate shareholders, or the name and contact information (City, State) of an individual representing the corporation or entity. Include Company Insiders who own any outstanding units or shares of any class of any equity security of the issuer.

The goal of this section is to provide investors with a clear understanding of the identity of all the persons or entities that are involved in managing, controlling or advising the operations, business development and disclosure of the issuer, as well as the identity of any significant or beneficial owners.

Names of All Officers, Directors, and Control Persons	Affiliation with Company (e.g. Officer Title /Director/Owner of 5% or more)	Residential Address (City / State Only)	Number of shares owned	Share type/class	Ownership Percentage of Class Outstanding	Names of control person(s) if a corporate entity
Guy Zajonc	Chairman and CEO	Spokane, WA	1,961,000,000	Common	26.99%	
Michelle Pfeffer	Director and President	Kamuela, HI	1,147,000,000	Common	15.78%	
Hacket, CP,	5%+ Shareholder	Australia	430,595,270	Common	5.93%	Simon Hackett

Confirm that the information in this table matches your public company profile on www.OTCMarkets.com. If any updates are needed to your public company profile, log in to www.OTCIQ.com to update your company profile.

7) Legal/Disciplinary History

A. Identify and provide a brief explanation as to whether any of the persons or entities listed above in Section 6 have, in the past 10 years:

1. Been the subject of an indictment or conviction in a criminal proceeding or plea agreement or named as a defendant in a pending criminal proceeding (excluding minor traffic violations);

None

2. Been the subject of the entry of an order, judgment, or decree, not subsequently reversed, suspended or vacated, by a court of competent jurisdiction that permanently or temporarily enjoined, barred, suspended or otherwise limited such person's involvement in any type of business, securities, commodities, financial- or investment-related, insurance or banking activities;

None

3. Been the subject of a finding, disciplinary order or judgment by a court of competent jurisdiction (in a civil action), the Securities and Exchange Commission, the Commodity Futures Trading Commission, a state securities regulator of a violation of federal or state securities or commodities law, or a foreign regulatory body or court, which finding or judgment has not been reversed, suspended, or vacated;

None

4. Named as a defendant or a respondent in a regulatory complaint or proceeding that could result in a "yes" answer to part 3 above; or

None

5. Been the subject of an order by a self-regulatory organization that permanently or temporarily barred, suspended, or otherwise limited such person's involvement in any type of business or securities activities.

None

8. Been the subject of a U.S Postal Service false representation order, or a temporary restraining order, or preliminary injunction with respect to conduct alleged to have violated the false representation statute that applies to U.S mail.

None

- B. Describe briefly any material pending legal proceedings, other than ordinary routine litigation incidental to the business, to which the issuer or any of its subsidiaries is a party to or of which any of their property is the subject. Include the name of the court or agency in which the proceedings are pending, the date instituted, the principal parties thereto, a description of the factual basis alleged to underlie the proceeding and the relief sought. Include similar information as to any such proceedings known to be contemplated by governmental authorities.

None

8) Third Party Service Providers

Provide the name, address, telephone number and email address of each of the following outside providers. You may add additional space as needed.

Confirm that the information in this table matches your public company profile on www.OTCMarkets.com. If any updates are needed to your public company profile, update your company profile.

Securities Counsel (must include Counsel preparing Attorney Letters).

Name: JDT Legal (Jeff Turner)
Address 1: 7533 S Center View Ct #4291
Address 2: West Jordan, UT, 84084
Phone: 801-810-4465
Email: jeff@jdt-legal.com

Accountant or Auditor

Name: _____
Firm: _____
Address 1: _____
Address 2: _____
Phone: _____
Email: _____

Investor Relations

Name: _____
Firm: _____
Address 1: _____
Address 2: _____
Phone: _____
Email: _____

All other means of Investor Communication:

X (Twitter): https://twitter.com/precisiont67828?s=11&t=R3mPh1hAvj9m1R3p__8NIA
Discord: _____

LinkedIn <https://www.linkedin.com/company/thrive-precision-health1/>
Facebook: <https://www.facebook.com/profile.php?id=100092725167875>
[Other] www.thriveprecision.health

Other Service Providers

Provide the name of any other service provider(s) that **that assisted, advised, prepared, or provided information with respect to this disclosure statement**. This includes counsel, broker-dealer(s), advisor(s), consultant(s) or any entity/individual that provided assistance or services to the issuer during the reporting period.

Name: Gary Bartholomew
Firm: CyberNorth Ventures, Inc
Nature of Services: Technology Consulting
Address 1: 2 Campbell Dr, Ste 820
Address 2: Uxbridge, ON Canada, L9P0A3
Phone:
Email: gary@cybernorthventures.com

9) Disclosure & Financial Information

A. This Disclosure Statement was prepared by (name of individual):

Name: **Gary Bartholomew**
Title: **CEO**
Relationship to Issuer: **Officer**

B. The following financial statements were prepared in accordance with:

- IFRS
 U.S. GAAP

C. The following financial statements were prepared by (name of individual):

Name: **Brett Vorman**
Title: **Consultant**
Relationship to Issuer: **Consultant**

Describe the qualifications of the person or persons who prepared the financial statements:⁵ **20 years financial accounting experience**

Provide the following qualifying financial statements:

- Balance Sheet;
- Statement of Income;
- Statement of Cash Flows;

⁵ The financial statements requested pursuant to this item must be prepared in accordance with US GAAP or IFRS and by persons with sufficient financial skills.

- Statement of Retained Earnings (Statement of Changes in Stockholders' Equity)
- Financial Notes

Financial Statement Requirements:

- Financial statements must be published together with this disclosure statement as one document.
- Financial statements must be “machine readable”. Do not publish images/scans of financial statements.
- Financial statements must be presented with comparative financials against the prior FYE or period, as applicable.
- Financial statements must be prepared in accordance with U.S. GAAP or International Financial Reporting Standards (IFRS) but are not required to be audited.

10) Issuer Certification

Principal Executive Officer:

The issuer shall include certifications by the chief executive officer and chief financial officer of the issuer (or any other persons with different titles but having the same responsibilities) in each Quarterly Report or Annual Report.

The certifications shall follow the format below:

I, certify that:

1. I have reviewed this Disclosure Statement for CHINA NEW ENERGY GROUP COMPANY;
2. Based on my knowledge, this disclosure statement does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this disclosure statement; and
3. Based on my knowledge, the financial statements, and other financial information included or incorporated by reference in this disclosure statement, fairly present in all material respects the financial condition, results of operations and cash flows of the issuer as of, and for, the periods presented in this disclosure statement.

November 12, 2024

/s/ Gary Bartholomew [CEO's Signature]

(Digital Signatures should appear as "/s/ [OFFICER NAME]")

Principal Financial Officer:

I, Gary Bartholomew certify that:

1. I have reviewed this Disclosure Statement for China New Energy Group Company;
2. Based on my knowledge, this disclosure statement does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this disclosure statement; and

3. Based on my knowledge, the financial statements, and other financial information included or incorporated by reference in this disclosure statement, fairly present in all material respects the financial condition, results of operations and cash flows of the issuer as of, and for, the periods presented in this disclosure statement.

November 12, 2024 [Date]

/s/ Gary Bartholomew [CFO's Signature]

(Digital Signatures should appear as "/s/ [OFFICER NAME]")

**CHINA NEW ENERGY GROUP CO.
CONDENSED CONSOLIDATED BALANCE SHEETS**

	September 30, 2024	December 31, 2023
	<u>(unaudited)</u>	<u>(unaudited)</u>
ASSETS		
Current assets:		
Cash and cash equivalents	\$ 6,801	\$ 832
Advances	-	525,782
Total current assets	<u>6,801</u>	<u>526,614</u>
Total assets	<u>\$ 6,801</u>	<u>\$ 526,614</u>
LIABILITIES AND STOCKHOLDER'S EQUITY		
Current liabilities:		
Accounts payable	\$ -	\$ 25,417
Accrued expenses and other current liabilities	58,606	30,951
Convertible notes payable	1,477,915	398,932
Notes payable	-	7,500
Total current liabilities	<u>1,536,521</u>	<u>462,800</u>
Total liabilities	<u>\$ 1,536,521</u>	<u>\$ 462,800</u>
Stockholders' equity:		
Preferred stock, \$0.001 par value, 10,000,000,000 shares authorized and 0 and 10,000,000 shares outstanding at September 30, 2024 and December 31, 2023, respectively	\$ -	\$ -
Common stock, \$0.001 par value, 500,000,000 shares authorized and 7,342,532,492 shares outstanding at September 30, 2024 and December 31, 2023, respectively	7,342,532	7,342,532
Additional paid-in capital	(21,153,084)	(21,153,084)
Retained earnings	12,280,832	13,874,366
Total stockholder's equity (deficit)	<u>(1,529,720)</u>	<u>63,814</u>
Total liabilities and stockholders' equity	<u>\$ 6,801</u>	<u>\$ 526,614</u>

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

CHINA NEW ENERGY GROUP CO.
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
(UNAUDITED)

	For the Three Months Ended September 30,		For the Nine Months Ended September 30,	
	2024	2023	2024	2023
Revenues, net	\$ -	\$ -	\$ -	\$ -
Cost of revenues	-	-	-	-
Gross profit	-	-	-	-
Operating expenses:				
Selling, general and administrative expenses	242,961	119,461	501,988	431,720
Impairment	14,715	-	1,041,900	-
Total operating expenses	257,676	119,461	1,543,888	431,720
Operating loss	(257,676)	(119,461)	(1,543,888)	(431,720)
Non-operating income (expense):				
Interest expense	(21,940)	-	(49,646)	(1,588)
Total non-operating income (expense)	(21,940)	-	(49,646)	(1,588)
Net income (loss) before income tax expense	(279,616)	(119,461)	(1,593,534)	(433,308)
Income tax expense (benefit)	-	-	-	-
Net loss	\$ (279,616)	\$ (119,461)	(1,593,534)	(433,308)
Earnings (loss) per share:				
Loss per share – basic and diluted	\$ (0.00)	\$ (0.00)	\$ (0.00)	\$ (0.00)
Weight average number of common shares outstanding – basic and diluted	7,342,532,492	7,266,940,246	7,342,532,492	5,375,049,843

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

CHINA NEW ENERGY GROUP CO.
CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDER'S DEFICIT
For the Nine Months Ended September 30, 2024 (unaudited) and 2023 (unaudited)

	<u>Common Stock</u>		<u>Additional Paid in Capital</u>	<u>Preferred Stock</u>		<u>Retained Earnings</u>	<u>Total</u>
	<u>Shares</u>	<u>Amount</u>		<u>Shares</u>	<u>Amount</u>		
Balances, January 1, 2024	7,342,532,492	\$ 7,342,532	\$ (21,153,084)	-	\$ -	13,874,366	\$ 63,814
Issuance of common stock	-	-	-	-	-	-	-
Net loss	-	-	-	-	-	(1,593,534)	(1,593,534)
Balances, September 30, 2024	<u>7,342,532,492</u>	<u>\$ 7,342,532</u>	<u>\$ (21,153,084)</u>	<u>-</u>	<u>\$ -</u>	<u>12,280,832</u>	<u>\$ (1,529,720)</u>
Balances, January 1, 2023	107,070,281	\$ 107,070	\$ (14,827,344)	10,000,000	\$ 10,000	14,693,836	\$ (16,438)
Issuance of common stock – reverse takeover	7,071,193,360	7,071,193	(7,061,193)	(10,000,000)	(10,000)	-	-
Issuance of common stock – investors	88,676,605	88,677	205,123	-	-	-	293,800
Net loss	-	-	-	-	-	(433,308)	(433,308)
Balances, September 30, 2023	<u>7,266,940,246</u>	<u>\$ 7,266,940</u>	<u>\$ (21,683,414)</u>	<u>-</u>	<u>\$ -</u>	<u>14,260,528</u>	<u>\$ (155,946)</u>

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

CHINA NEW ENERGY GROUP CO.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
(Unaudited)

1. NATURE OF OPERATIONS AND BASIS OF PRESENTATION

China New Energy Group Company. (“CNER” or the “Company”) plans to work with leading research and development companies around the world to license enabling technology for the delivery of Biosafety as a Service (“BaaS”) to Points of Entry (Airports, Sporting Events, Schools, Business) and to develop a concierge service whereby testing can be ordered and performed on demand at the doorstep of your home or business. CNER’s purpose is to protect people and places from pathogens such as bacteria, viruses, fungus, spores, mold and toxins. Additionally, CNER has shifted its focus to developing technologies for diabetes care and deploying these technologies with clinics they are acquiring or building.

China New Energy Group Company was originally incorporated in the state of Delaware and redomiciled in the state of Wyoming. On April 3, 2023, the corporate name China New Energy Group Company was changed to Thrive Global Biosafety Inc and then changed to Thrive Precision Health Inc. (“Thrive”).

As of June 30, 2024, the Company had four wholly-owned subsidiaries: Thrive Testing and Biosafety Inc., incorporated in the State of Wyoming, Thrive Precision Health Hawaii, Inc., incorporated in the state of Hawaii, Thrive Precision Health USA Inc., incorporated in the state of Wyoming, and Thrive Precision Health, Inc., incorporated in the state of Nevada (“TPHI-NV”).

On June 7, 2024, the Company formed TPHI-NV in anticipation of completing a spinoff of certain assets and liabilities of the Company. On June 7, 2024, TPHI-NV assumed the assets and liabilities of Thrive Precision Health, Inc. (“TPHI-FL”), a Florida corporation, previously owned by the Chief Executive Officer of the Company. TPHI-FL was dissolved on June 18, 2024.

On July 3, 2024, Thrive Precision Health Inc., a subsidiary of China New Energy Group Company issued a Promissory Note to a Lender with the principle around of \$250,000, accruing interest at a rate of 6% annually. The Note matures on July 4, 2025, if not converted with a registered financing before such time.

On July 18, 2024, the Company, perfected its security on True Neuropathy and Wound Solutions Inc., (Borrower) against the secured promissory note executed May 31, 2024 and having advanced \$902,585 in loan funds for support of ongoing clinical operations of the Borrower. Repayment demand was made in accordance of the Secure Promissory Note and the Borrower defaulted on repayment.

On July 31, 2024, all clinical operations ceased, all staff we terminated, and all creditors notified of the liquidation. The Company will now process, acting as trustee, dissolve all operations of the Borrower. The Company recorded an impairment charge during the three months ended June 30, 2024.

On September 27, 2024, China New Energy Group Company, made the decision to not pursue a spin off arrangement of the Thrive Precision Health subsidiaries due to cost and regulatory complexities relative to the value of these assets. All corporate actions were terminated.

Liquidity Uncertainties.

As of September 30, 2024, the Company had \$6,801 in cash and cash equivalents as compared to \$832 at December 31, 2023. The Company expects that its current cash and cash equivalents will not be sufficient to support its projected operating requirements for at least the next 12 months from this date.

The Company expects to need additional capital in order to generate revenues. Any additional equity financing, if available, may not be on favorable terms and would likely be significantly dilutive to the Company’s current stockholders, and debt financing, if available, may involve restrictive covenants. The Company’s ability to access capital when needed is not assured and, if not achieved on a timely basis, will likely have a materially adverse effect on our business, financial condition and results of operations.

Basis of Presentation.

The accompanying unaudited condensed consolidated financial statements of the Company have been prepared in accordance with accounting principles generally accepted in the United States of America ("US GAAP"). All significant intercompany transactions and balances have been eliminated in consolidation.

CHINA NEW ENERGY GROUP CO. **NOTES TO CONSOLIDATED FINANCIAL STATEMENTS** *(Unaudited)*

2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

Use of Estimates. The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amount of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from these estimates. The Company's significant estimates used in these unaudited condensed consolidated financial statements include, but are not limited to, revenue recognition and the determination of the economic useful life of depreciable property and equipment. Certain of the Company's estimates could be affected by external conditions, including those unique to the Company and general economic conditions. It is reasonably possible that these external factors could have an effect on the Company's estimates and could cause actual results to differ from those estimates.

Cash and Cash Equivalents. The Company considers all highly liquid, short-term investments with original maturities of three months or less when purchased to be cash equivalents.

Contingent Liabilities. The Company, from time to time, may be involved in certain legal proceedings. Based upon consultation with outside counsel handling its defense in these matters and the Company's analysis of potential outcomes, if the Company determines that a loss arising from such matters is probable and can be reasonably estimated, an estimate of the contingent liability is recorded in its unaudited condensed consolidated financial statements. If only a range of estimated loss can be determined, an amount within the range that, based on estimates, assumptions and judgments, reflects the most likely outcome, is recorded as a contingent liability in the unaudited condensed consolidated financial statements. In situations where none of the estimates within the estimated range is a better estimate of probable loss than any other amount, the Company records the low end of the range. Any such accrual would be charged to expense in the appropriate period. Litigation expenses for these types of contingencies are recognized in the period in which the litigation services were provided.

Earnings Per Share. The Company follows ASC 260 when reporting Earnings Per Share resulting in the presentation of basic and diluted earnings per share. Basic net (loss) income per common share is computed by dividing net (loss) income by the weighted average number of vested common shares outstanding during the period. Diluted net income per common share is computed by dividing net income by the weighted average number vested of common shares, plus the net impact of common shares (computed using the treasury stock method), if dilutive, resulting from the exercise of dilutive securities. In periods when losses are reported, the weighted-average number of common shares outstanding excludes common stock equivalents because their inclusion would be anti-dilutive.

Income Taxes. The Company accounts for income taxes under the provisions of the FASB ASC Topic 740 "Income Taxes" ("ASC Topic 740"). The Company recognizes deferred tax assets and liabilities for the expected future tax consequences of items that have been included or excluded in the unaudited condensed consolidated financial statements or tax returns. Deferred tax assets and liabilities are determined on the basis of the difference between the tax basis of assets and liabilities and their respective financial reporting amounts ("temporary differences") at enacted tax rates in effect for the years in which the temporary differences are expected to reverse. The Company utilizes a recognition threshold and measurement process for financial statement recognition and measurement of a tax position taken or expected to be taken in a tax return. Management has evaluated and concluded that there were no material uncertain tax positions requiring recognition in the Company's unaudited condensed consolidated financial statements as of December 31, 2023 and 2022. The Company does not expect any significant changes in its unrecognized tax benefits within twelve months of the reporting date. The Company's policy is to classify assessments, if any, for tax related interest as interest expense and penalties as general and administrative expenses in the consolidated statements of comprehensive income. The Company is subject to routine audits by taxing jurisdictions; however, there are currently no audits for any tax periods in progress.

CHINA NEW ENERGY GROUP CO.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
(Unaudited)

2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES, CONTINUED

Fair Value Measurements. The Company measures the fair value of financial assets and liabilities based on the guidance of ASC 820 “Fair Value Measurements and Disclosures” (“ASC 820”) which defines fair value, establishes a framework for measuring fair value, and expands disclosures about fair value measurements.

ASC 820 defines fair value as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. ASC 820 also establishes a fair value hierarchy, which requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. ASC 820 describes three levels of inputs that may be used to measure fair value:

- Level 1 — quoted prices in active markets for identical assets or liabilities
- Level 2 — quoted prices for similar assets and liabilities in active markets or inputs that are observable
- Level 3 — inputs that are unobservable (for example, cash flow modeling inputs based on assumptions)

The carrying amounts of the Company’s financial instruments, such as cash, accounts receivable, accounts payable and other current liabilities approximate fair values due to the short-term nature of these instruments. The Company’s debt consists of \$406,432. The estimated fair value of this debt approximates the carrying value of these instruments, due to the interest rates on this debt approximating current market interest rates.

Concentration of Credit Risks. Financial instruments that potentially subject the Company to concentrations of credit risk are cash equivalents and accounts receivable. Cash and cash equivalents are invested in deposits with certain financial institutions and may, at times, exceed federally insured limits. The Company has not experienced any significant losses on its deposits of cash and cash equivalents. In regard to trade receivables, the Company performs ongoing evaluations of its customers’ financial condition as well as general economic conditions and, generally, requires no collateral from its customers.

Recent Accounting Pronouncements. In June 2016, the FASB issued ASU No. 2016-13, Financial Instruments – Credit Losses (Topic 326), Measurement of Credit Losses on Financial Instruments, as modified by FASB ASU No. 2019-10 and other subsequently issued related ASUs. The amendments in this Update affect loans, debt securities, trade receivables, and any other financial assets that have the contractual right to receive cash. The ASU requires an entity to recognize expected credit losses rather than incurred losses for financial assets. The amendments in this Update are effective for fiscal years beginning after December 15, 2022, including interim periods within those fiscal years. The Company adopted this new guidance effective January 1, 2023 utilizing the modified retrospective transition method. The adoption of this standard did not have a material impact on the Company’s financial statements, but did change how the allowance for credit losses is determined.

3. ADVANCES

Advances, represents cash provided to acquisition targets. The cash advances are due on demand and do not bear interest. Advances was as follows at September 30, 2024 and December 31, 2023, respectively:

	September 30, 2024	December 31, 2023
Insulinic Hawaii, 0%	-	82,000
True Neuropathy and Wound Solutions, Inc., 0%	-	443,782
Advances, net	\$ -	\$ 525,782

On September 1, 2023, Thrive Precision Health Inc., signed an agreement to purchase 100% of the assets of True Diabetes Neuropathy and Wounds Solutions LLC (“True”) which includes their Gilbert and Show Low locations in Arizona. The Company is no longer planning to acquire True.

On May 31, 2024, the Company converted \$902,585 of the advances to True into a 6% promissory note receivable related to the previous cash advances provided by the Company to True for the working capital needs in the clinics. See Note 4.

The Company recorded impairment charges of \$14,715 and \$139,315 related to its cash advances to Insulinic Hawaii and True for the three and nine months ended September 30, 2024, respectively. The Company did not have any impairment charges for the three and nine months ended September 30, 2023, respectively.

On July 18, 2024, the Company perfected its security on True against the secured promissory note executed May 31, 2024 and having advanced \$902,585 in loan funds for support of ongoing clinical operations of the Borrower. Repayment demand was made in accordance of the Secure Promissory Note and the Borrower defaulted on repayment. On July 31, 2024, all clinical operations ceased, all staff we terminated, and all creditors notified of the liquidation. The Company will now process, acting as trustee, dissolve all operations of the Borrower.

CHINA NEW ENERGY GROUP CO.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
(Unaudited)

4. NOTES RECEIVABLE

Principal due under notes receivable was as follows at September 30, 2024 and December 31, 2023, respectively:

	<u>September 30, 2024</u>	<u>December 31, 2023</u>
True, 6%	902,585	-
True Neuropathy and Wound Solutions, Inc., 0%	(902,585)	-
Notes receivable, net	<u>\$ -</u>	<u>\$ -</u>

On May, 31, 2024, the Company entered into a 6% promissory note receivable with True in the amount of \$902,585. The note receivable is due on demand. The note is collateralized by 100% of all the issued and outstanding common shares of True.

For the three and nine months ended September 30, 2024, the Company recorded a full impairment charge of \$0 and \$902,585, respectively, on its note receivable from True, reflecting the total amount from True due to the uncertainty of collectability. The impairment is recorded as an expense in the unaudited condensed consolidated statement of operations. The Company did not have any impairment charges for the three and six months ended June 30, 2023, respectively.

5. ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES

Accrued expenses and other current liabilities consist of the following at September 30, 2024 and December 31, 2023, respectively:

	<u>September 30, 2024</u>	<u>December 31, 2023</u>
Due to related parties	\$ -	\$ 24,398
Accrued interest	43,606	3,494
Other	<u>15,000</u>	<u>3,060</u>

Total accrued expenses and other current liabilities	\$ 58,606	\$ 30,951
--	-----------	-----------

6. CONVERTIBLE NOTES PAYABLE

Principal due under the convertible notes payable was as follows at September 30, 2024 and December 31, 2023, respectively:

	<u>September 30, 2024</u>	<u>December 31, 2023</u>
Wallace Notes, 6%	418,381	348,932
DeBell Note, 6%	50,000	50,000
Knutz Holdings, LLC, 6%	1,009,534	-
Convertible notes payable, net	<u>\$ 1,477,915</u>	<u>\$ 398,932</u>

On August 18, 2023, the Company provided a financial guarantee for \$98,932 and \$49,449 to be settled in the common restricted shares of the Company at a price of \$0.01 share. Proceeds of the loan were used to fund clinical operations of True Diabetes Neuropathy and Wounds Solutions LLC located in Arizona.

On November 24, 2023, the Company entered into a convertible promissory note worth \$50,000 that converts upon a registered financing at the registered price.

On December 8, 2023, the Company entered into a convertible promissory note worth \$250,000 that converts upon a registered financing at the registered price.

On January 30, 2024, the Company entered into a convertible promissory note worth \$25,000 that converts upon a registered financing at the registered price of which \$5,000 was repaid in 2024.

On June 7, 2024, TPHI-NV entered in the convertible promissory note worth \$759,534 that converts upon a registered financing at the registered price. TPHI-FL received aggregate proceeds of \$750,000 from Knutz Holdings of \$250,000 each on February 22, 2024, March 18, 2024 and April 17, 2024, respectively.

On July 3, 2024, TPHI-NV issued a Promissory Note to a Borrower with the principle around of \$250,000, accruing interest at a rate of 6% annually. The Note matures on July 4, 2025, if not converted with a registered financing before such time.

Interest expense under convertible notes payable was \$21,940 and \$49,646 for the three and nine months ended September 30, 2024, respectively. Interest expense under convertible notes payable was \$0 and \$0 for the three and nine months ended September 30, 2023, respectively.

7. NOTES PAYABLE

Principal due under the notes payable was as follows at September 30, 2024 and December 31, 2023, respectively:

	<u>September 30, 2024</u>	<u>December 31, 2023</u>
Elysian Essential Oils LLC Note, 6%	-	7,500
Note payable, net	<u>\$ -</u>	<u>\$ 7,500</u>

**CHINA NEW ENERGY GROUP CO.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS**

(Unaudited)

On August 22, 2023, Thrive Precision Health Inc., entered into a \$20,000 Promissory Note with Elysian Essential Oils LLC, an entity owned by David Anderson a shareholder of Thrive Precision Health, accruing interest at 6% annually with a 120-day term. The Company has fully repaid the promissory note with Elysian Essential Oils LLC as of September 30, 2024. Interest expense under notes payable was \$0 and \$1,588 for the three and nine months ended September 30, 2023, respectively.

8. STOCKHOLDERS' EQUITY

Common Stock.

As of September 30, 2024 and December 31, 2023, respectively, the Company's outstanding and authorized common shares and shareholders were as follows:

September 30, 2024

- 10,000,000,000 shares of common stock authorized
- 7,342,532,492 shares of common stock outstanding
- 535,941,611 common shares are unrestricted:
- 195 shareholders of record

December 31, 2023

- 10,000,000,000 shares of common stock authorized
- 7,342,532,492 shares of common stock outstanding
- 535,941,611 common shares are unrestricted:
- 195 shareholders of record

On May 1, 2024, the Company entered into a medical directorship agreement with Dr. Ky Le to provide clinical advisory services. The Company agreed to pay Dr. Ky Le \$2,000 per month per contracted location and grant 500,000 deferred share units ("DSUs").

9. COMMITMENTS AND CONTINGENCIES

Operating Leases. The Company was not committed to any operating leases.

10. SUBSEQUENT EVENTS

On October 1, 2024, The Board of Directors of China New Energy Group Company elected Gary Bartholomew and to the Board of Directors and elected Gary Bartholomew as CEO and Treasurer. At that time Directors and officers, Guy Zajonc and Michael Pfeffer resigned their positions. Gary Bartholomew now acts as sole director, secretary, treasurer, CEO and CFO.

On October 23, 2024, China New Energy Group Company entered into a Debt Settlement Agreement with Thrive Health Inc., whereas Thrive Health Inc., will assume the debt associated with the convertible promissory notes as of the effective date totaling \$1,198,916 in return for assignment of all the shares owned by China New Energy Group Company of Thrive Precision Health Inc., Thrive Precision Health Hawaii, Inc, Thrive Precision Health USA Inc. and Thrive Precision Health Innovations Inc. Any debt or payables held within these subsidiaries will remain within the subsidiary company and become the liability of Thrive Health Inc. The debt settlement will be reflected in the financial statements for the year ended December 31, 2024, impacting both the debt obligations and the equity of the Company accordingly.